Taiwan · Delayed Price · Currency is TWD Sofiva Genomics Statistics
Total Valuation
Sofiva Genomics has a market cap or net worth of TWD 726.62 million. The enterprise value is 633.14 million.
| Market Cap | 726.62M |
| Enterprise Value | 633.14M |
Important Dates
The next estimated earnings date is Wednesday, August 19, 2026.
| Earnings Date | Aug 19, 2026 |
| Ex-Dividend Date | Jun 27, 2025 |
Share Statistics
Sofiva Genomics has 21.59 million shares outstanding. The number of shares has increased by 0.43% in one year.
| Current Share Class | 21.59M |
| Shares Outstanding | 21.59M |
| Shares Change (YoY) | +0.43% |
| Shares Change (QoQ) | +0.53% |
| Owned by Insiders (%) | 5.59% |
| Owned by Institutions (%) | n/a |
| Float | 12.64M |
Valuation Ratios
The trailing PE ratio is 51.29.
| PE Ratio | 51.29 |
| Forward PE | n/a |
| PS Ratio | 1.92 |
| PB Ratio | 1.12 |
| P/TBV Ratio | 1.13 |
| P/FCF Ratio | 25.81 |
| P/OCF Ratio | 23.91 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.05, with an EV/FCF ratio of 22.49.
| EV / Earnings | 44.51 |
| EV / Sales | 1.67 |
| EV / EBITDA | 13.05 |
| EV / EBIT | 40.77 |
| EV / FCF | 22.49 |
Financial Position
The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.06.
| Current Ratio | 3.54 |
| Quick Ratio | 3.03 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 2.67 |
| Debt / FCF | 1.36 |
| Interest Coverage | -27.18 |
Financial Efficiency
Return on equity (ROE) is 2.30% and return on invested capital (ROIC) is -2.68%.
| Return on Equity (ROE) | 2.30% |
| Return on Assets (ROA) | -1.57% |
| Return on Invested Capital (ROIC) | -2.68% |
| Return on Capital Employed (ROCE) | -2.79% |
| Weighted Average Cost of Capital (WACC) | 5.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 104 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 7.76 |
Taxes
In the past 12 months, Sofiva Genomics has paid 3.77 million in taxes.
| Income Tax | 3.77M |
| Effective Tax Rate | 20.38% |
Stock Price Statistics
The stock price has increased by +9.25% in the last 52 weeks. The beta is 0.21, so Sofiva Genomics's price volatility has been lower than the market average.
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +9.25% |
| 50-Day Moving Average | 34.86 |
| 200-Day Moving Average | 32.95 |
| Relative Strength Index (RSI) | 43.65 |
| Average Volume (20 Days) | 12,009 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sofiva Genomics had revenue of TWD 379.21 million and earned 14.23 million in profits. Earnings per share was 0.66.
| Revenue | 379.21M |
| Gross Profit | 100.71M |
| Operating Income | -18.62M |
| Pretax Income | 18.48M |
| Net Income | 14.23M |
| EBITDA | 7.48M |
| EBIT | -18.62M |
| Earnings Per Share (EPS) | 0.66 |
Balance Sheet
The company has 131.52 million in cash and 38.30 million in debt, with a net cash position of 93.22 million or 4.32 per share.
| Cash & Cash Equivalents | 131.52M |
| Total Debt | 38.30M |
| Net Cash | 93.22M |
| Net Cash Per Share | 4.32 |
| Equity (Book Value) | 647.88M |
| Book Value Per Share | 29.85 |
| Working Capital | 175.72M |
Cash Flow
In the last 12 months, operating cash flow was 30.38 million and capital expenditures -2.24 million, giving a free cash flow of 28.15 million.
| Operating Cash Flow | 30.38M |
| Capital Expenditures | -2.24M |
| Depreciation & Amortization | 26.09M |
| Net Borrowing | -4.32M |
| Free Cash Flow | 28.15M |
| FCF Per Share | 1.30 |
Margins
Gross margin is 26.56%, with operating and profit margins of -4.91% and 3.75%.
| Gross Margin | 26.56% |
| Operating Margin | -4.91% |
| Pretax Margin | 4.87% |
| Profit Margin | 3.75% |
| EBITDA Margin | 1.97% |
| EBIT Margin | -4.91% |
| FCF Margin | 7.42% |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 0.89%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 0.89% |
| Dividend Growth (YoY) | 50.77% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 45.54% |
| Buyback Yield | -0.43% |
| Shareholder Yield | 0.47% |
| Earnings Yield | 1.96% |
| FCF Yield | 3.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |